SAFETY, TOLBERABILITY AND PHARMACOKINETICS OF MULTIPLE DOSES OF THE TRPV1 ANTAGONIST SAF312 IN HEALTHY SUBJECTS

被引：0
|
作者：
Schramm, U. [1 ]
Vaidya, S. [2 ]
Tavares, G. [3 ]
Roberts, J. [4 ]
Francke, K. [5 ]
El Mouelhi, M. [6 ]
机构：
[1] Novartis Inst BioMed Res Inc, Basel, Switzerland
[2] Novartis Inst BioMed Res Inc, Cambridge, Switzerland
[3] Novartis, Basel, Switzerland
[4] Novartis, E Hanover, NJ USA
[5] Parexel, Harrow, Middx, England
[6] Novartis Inst BioMedical Res Inc, E Hanover, NJ USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2014年 / 95卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：S68 / S69
页数：2
相关论文
共 50 条
  • [1] SAFETY, TOLERABILITY AND PHARMACOKINETICS OF SINGLE DOSES OF THE TRPV1 ANTAGONIST SAF312 IN HEALTHY SUBJECTS
    El Mouelhi, M.
    Bartlett, M.
    Roberts, J.
    Vaidya, S.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 95 : S68 - S68
  • [2] Ocular Pharmacology and Toxicology of TRPV1 Antagonist SAF312 (Libvatrep)
    Mogi, Muneto
    Mendonza, Anisha E.
    Chastain, James
    Demirs, John T.
    Medley, Quintus G.
    Zhang, Qin
    Papillon, Julien P. N.
    Yang, Junzheng
    Gao, Yan
    Xu, YongYao
    Stasi, Kalliopi
    TRANSLATIONAL VISION SCIENCE & TECHNOLOGY, 2023, 12 (09):
  • [3] Topical ocular TRPV1 antagonist SAF312 demonstrated safety, low systemic exposure, and no anesthetic effect in healthy volunteers
    Li, Yifang
    Jain, Monish
    Palmer, Michela
    Haque, Sameena
    Stasi, Kalliopi
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2021, 62 (08)
  • [4] Structural basis of TRPV1 inhibition by SAF312 and cholesterol
    Fan, Junping
    Ke, Han
    Lei, Jing
    Wang, Jin
    Tominaga, Makoto
    Lei, Xiaoguang
    NATURE COMMUNICATIONS, 2024, 15 (01)
  • [5] Topical Ocular TRPV1 Antagonist SAF312 (Libvatrep) Demonstrates Safety, Low Systemic Exposure, and No Anesthetic Effect in Healthy Participants
    Stasi, Kalliopi
    Alshare, Qusai
    Jain, Monish
    Wald, Michael
    Li, Yifang
    TRANSLATIONAL VISION SCIENCE & TECHNOLOGY, 2022, 11 (01):
  • [6] Topical Ocular TRPV1 Antagonist SAF312 (Libvatrep) for Postoperative Pain After Photorefractive Keratectomy
    Thompson, Vance
    Moshirfar, Majid
    Clinch, Thomas
    Scoper, Stephen
    Linn, Steven H.
    McIntosh, Avery
    Li, Yifang
    Eaton, Matt
    Ferriere, Michael
    Stasi, Kalliopi
    TRANSLATIONAL VISION SCIENCE & TECHNOLOGY, 2023, 12 (03):
  • [7] Topical ocular TRPV1 antagonist SAF312 was well tolerated and effectively reduced pain after photorefractive keratectomy (PRK)
    Stasi, Kalliopi
    Thompson, Vance
    Moshirfar, Wjid
    Clinch, Thomas
    Scoper, Stephen
    Linn, Steven
    McIntosh, Avery
    Li, Yifang
    Eaton, Matt
    Palmer, Michela Montecchi
    Haque, Sameena
    Ferriere, Michael
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2021, 62 (08)
  • [8] An investigation of the safety and pharmacokinetics of the novel TRPV1 antagonist XEN-D0501 in healthy subjects
    Round, Patrick
    Priestley, Anthony
    Robinson, Jan
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 72 (06) : 921 - 931
  • [9] PHARMACOKINETICS AND TOLERABILITY OF A NEW TRPV1 ANTAGONIST AFTER MULTIPLE ADMINISTRATIONS IN HEALTHY VOLUNTEERS.
    Cha, Y. J.
    Gu, N.
    Shin, D.
    Lim, K. S.
    Shin, S. G.
    Yu, K. S.
    Jang, I. J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2012, 91 : S71 - S72
  • [10] Safety, tolerability and pharmacokinetics (PK) of multiple doses of lecozotan, a novel 5HT1A antagonist, in healthy elderly subjects.
    Parks, V
    Raje, SV
    Patat, AA
    Plotka, A
    Astruc, B
    Chassard, D
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 79 (02) : P68 - P68
12345